MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Neuronetics Gross Profit 2011-2025 | STIM
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Neuronetics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.7 M | 43.7 M | 37.7 M | 47.3 M | 40.3 M | 30.8 M | 27.6 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.7 M | 27.6 M | 39.6 M |
Quarterly Gross Profit Neuronetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.1 M | 17.8 M | 15.7 M | - | 14 M | 12.2 M | 13.1 M | - | 11.8 M | 12.8 M | 11.4 M | - | 12.9 M | 12.3 M | 10.7 M | - | 10.7 M | 11.5 M | 10.1 M | 11.8 M | 9.79 M | 7.42 M | 8.66 M | 13.1 M | 11.8 M | 12.4 M | 9.92 M | 11.9 M | 10.7 M | 10 M | 7.7 M | 9.15 M | 7.86 M | 7.81 M | 5.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.8 M | 5.99 M | 11.3 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
30.6 M | $ 16.71 | -0.83 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 16.22 | 2.97 % | $ 175 M |  China |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.57 | -3.4 % | $ 2 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
53 M | $ 38.53 | -0.26 % | $ 1.07 B | USA |
 |
DarioHealth Corp.
DRIO
|
5.98 M | $ 11.99 | 0.84 % | $ 340 M | Israel |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
2.29 B | $ 66.15 | -1.22 % | $ 25.5 B | USA |
 |
Danaher Corporation
DHR
|
14.2 B | $ 226.11 | -0.17 % | $ 165 B | USA |
 |
Exact Sciences Corporation
EXAS
|
493 M | $ 101.52 | 0.01 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 26.92 | -0.81 % | $ 814 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 19.95 | -2.97 % | $ 1.07 B | USA |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
83.8 K | $ 3.29 | -8.24 % | $ 105 K | USA |
 |
Co-Diagnostics
CODX
|
2.63 M | $ 0.31 | -9.7 % | $ 9.1 M | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 221.67 | -0.25 % | $ 40.2 B | USA |
 |
Guardant Health
GH
|
144 M | $ 103.94 | 1.83 % | $ 12.8 B | USA |
 |
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
2.86 B | $ 133.75 | -0.83 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 196.94 | 2.05 % | $ 10.1 B | USA |
 |
Quotient Limited
QTNT
|
23.3 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 183.42 | 0.5 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
18.5 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Mettler-Toledo International
MTD
|
2.33 B | $ 1 405.95 | 0.86 % | $ 29.8 B | Schweiz |
 |
Myriad Genetics
MYGN
|
585 M | $ 6.96 | -3.47 % | $ 631 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 261.21 | -1.12 % | $ 21.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 181.89 | -2.51 % | $ 15 B |  Irlanda |
 |
NeoGenomics
NEO
|
290 M | $ 11.99 | 1.14 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
421 M | $ 6.78 | -1.16 % | $ 1.47 B | USA |
 |
IDEXX Laboratories
IDXX
|
2.38 B | $ 698.37 | -0.83 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
988 M | $ 67.15 | 0.79 % | $ 4.65 B | USA |
 |
Agilent Technologies
A
|
2.84 B | $ 139.73 | 0.05 % | $ 42.5 B | USA |
 |
Biomerica
BMRA
|
498 K | $ 2.43 | -4.8 % | $ 5.58 M | USA |
 |
Bioventus
BVS
|
328 M | $ 7.53 | -0.26 % | $ 472 M | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
Pacific Biosciences of California
PACB
|
52.8 M | $ 2.1 | -1.18 % | $ 533 M | USA |